RNA 250516 28.00C(RNA250516C28000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

RNA250516C28000

Watchlist

1.96
+0.26+15.29%

15min DelayClose May 15 16:00 ET

1.96High1.72Low

Intraday

5D
Daily

News

BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $48
Moomoo News12:31 ET · Ratings
H.C. Wainwright Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $68
Moomoo NewsMay 12 11:31 ET · Ratings
Avidity Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMay 12 07:53 ET · Ratings
Avidity Biosciences Price Target Cut to $68.00/Share From $72.00 by HC Wainwright & Co.
Dow JonesMay 12 07:53 ET · Ratings
Scotiabank Sticks to Its Buy Rating for Avidity Biosciences (RNA)
TipRanksMay 9 08:35 ET · Ratings
Express News | Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
BenzingaMay 9 06:48 ET

Comments

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

$Avidity Biosciences (RNA.US)$
Breakthrough DM1 Drug Achieves Major Milestone: Japan Grants Rare Disease Status

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

$Avidity Biosciences (RNA.US)$
Major Breakthrough: Avidity's Muscular Dystrophy Drug Achieves Unprecedented Disease Control in Clinical Trial

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duc

$Avidity Biosciences (RNA.US)$
Avidity's DMD Drug Achieves 40% Exon Skipping Success, Transforming Duchenne Treatment

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duc

Dec 12, 2024 23:52

$Avidity Biosciences (RNA.US)$ Am I missing something? This stock has dropped so much over the last month and I don’t see any bad news 🧐

1

Sep 24, 2024 04:13

$Avidity Biosciences (RNA.US)$

Read more